Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · IEX Real-Time Price · USD
1.860
+0.110 (6.29%)
At close: May 2, 2024, 4:00 PM
1.870
+0.010 (0.54%)
After-hours: May 2, 2024, 7:40 PM EDT
Xeris Biopharma Holdings Revenue
In the year 2023, Xeris Biopharma Holdings had annual revenue of $163.91M with 48.68% growth. Revenue in the quarter ending December 31, 2023 was $44.39M with 33.93% year-over-year growth.
Revenue (ttm)
$163.91M
Revenue Growth
+48.68%
P/S Ratio
1.68
Revenue / Employee
$434,785
Employees
377
Market Cap
275.75M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 163.91M | 53.67M | 48.68% |
Dec 31, 2022 | 110.25M | 60.66M | 122.32% |
Dec 31, 2021 | 49.59M | 29.16M | 142.67% |
Dec 31, 2020 | 20.44M | 17.71M | 650.73% |
Dec 31, 2019 | 2.72M | 299.00K | 12.34% |
Dec 31, 2018 | 2.42M | 867.00K | 55.72% |
Dec 31, 2017 | 1.56M | 481.00K | 44.74% |
Dec 31, 2016 | 1.08M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sharecare | 445.25M |
Vanda Pharmaceuticals | 192.64M |
ChromaDex | 83.57M |
Poseida Therapeutics | 64.70M |
Adaptimmune Therapeutics | 60.28M |
Nanobiotix | 40.23M |
TriSalus Life Sciences | 18.51M |
Verrica Pharmaceuticals | 5.12M |
XERS News
- 14 hours ago - Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 - Business Wire
- 4 weeks ago - Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference - Business Wire
- 2 months ago - Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events - Business Wire
- 2 months ago - Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital - Business Wire
- 2 months ago - Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024 - Business Wire
- 3 months ago - Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference - Business Wire
- 4 months ago - Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab - Business Wire